Deborah D Schaefer

US Patent:

8394379, Mar 12, 2013

Filed:

Jan 13, 2010

Appl. No.:

12/686879

Inventors:

Michael Imboden - Madison WI, US
Michael Warren Riggs - Tucson AZ, US
Deborah A. Schaefer - Tucson AZ, US
Jane Homan - Hillpoint WI, US

Assignee:

ioGenetics, LLC - Madison WI

International Classification:

A61K 39/00
A61K 39/395

US Classification:

4241341, 4241331, 4241411, 4241511

Abstract:

The present invention relates to fusion proteins comprising a microorganism targeting molecule (e. g. , immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.

US Patent:

20060147442, Jul 6, 2006

Filed:

Oct 20, 2005

Appl. No.:

11/254500

Inventors:

Jane Homan - Hillpoint WI, US
Michael Imboden - Madison WI, US
Michael Riggs - Tuscon AZ, US
Stephane Carryn - Brussels, BE
Deborah Schaefer - Tuscon AZ, US

Assignee:

ioGenetics - Madison WI
University of Arizona - Tucson AZ

International Classification:

A61K 38/47

US Classification:

424094610

Abstract:

The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).

US Patent:

20070104722, May 10, 2007

Filed:

Oct 10, 2006

Appl. No.:

11/545601

Inventors:

Michael Imboden - Madison WI, US
Michael Riggs - Tuscon AZ, US
Deborah Schaefer - Tuscon AZ, US

Assignee:

ioGenetics - Madison WI
University of Arizona - Tucson AZ

International Classification:

A61K 39/40
C07K 16/12

US Classification:

424164100, 530388400

Abstract:

The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzyme) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense.

US Patent:

20100034824, Feb 11, 2010

Filed:

Aug 5, 2009

Appl. No.:

12/536291

Inventors:

Michael Imboden - Madison WI, US
Michael Riggs - Tucson AZ, US
Deborah A. Schaefer - Tuscon AZ, US

Assignee:

IOGENETICS, LLC - Madison WI
THE ARIZONA BOARD OF REGENTS - Tucson AZ

International Classification:

A61K 39/395
A61P 33/02
A61P 37/04

US Classification:

4241391, 4241511, 4241781

Abstract:

The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzyme) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense.

US Patent:

20130230516, Sep 5, 2013

Filed:

Feb 6, 2013

Appl. No.:

13/760448

Inventors:

Michael Imboden - Madison WI, US
Michael Riggs - Tucson AZ, US
Deborah A. Schaefer - Tuscon AZ, US
Jane Homan - Hillpoint WI, US
Robert D. Bremel - Hillpoint WI, US

Assignee:

Arizona Board of Regents on behalf of the University of Arizona - Tucson AZ
ioGenetics, LLC - Madison WI

International Classification:

C07K 16/20

US Classification:

4241341, 5303873

Abstract:

The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.